RareCan
2 known investors
RareCan provides tumour genomic analysis and plain-language interpretation to help people living with rare or less common cancers understand their tumour biology and identify relevant UK clinical trials and treatment options. It serves patients, particularly those who have exhausted standard treatments, offering personalised reports and clarity about their care options.
Investors · 2
Frequently asked questions
- What does RareCan do?
- RareCan provides tumour genomic analysis and plain-language interpretation to help people living with rare or less common cancers understand their tumour biology and identify relevant UK clinical trials and treatment options. It serves patients, particularly those who have exhausted standard treatments, offering personalised reports and clarity about their care options.
- Who are RareCan's investors?
- RareCan's investors include Anglia Capital Group, Cambridge Angels group.